Vamil Divan
Stock Analyst at Guggenheim
(4.44)
# 249
Out of 4,883 analysts
236
Total ratings
61.49%
Success rate
14.31%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JBIO Jade Biosciences | Upgrades: Buy | $14 | $10.84 | +29.15% | 1 | Jun 16, 2025 | |
| SVRA Savara | Maintains: Buy | $9 → $8 | $2.10 | +280.95% | 1 | May 28, 2025 | |
| AMGN Amgen | Assumes: Neutral | $288 | $296.85 | -2.98% | 1 | May 20, 2025 | |
| ANIP ANI Pharmaceuticals | Reiterates: Buy | $86 | $65.26 | +31.79% | 11 | May 12, 2025 | |
| VALN Valneva SE | Maintains: Buy | $15 → $14 | $5.81 | +140.96% | 1 | May 8, 2025 | |
| ABBV AbbVie | Maintains: Buy | $214 → $216 | $190.75 | +13.24% | 26 | Apr 29, 2025 | |
| UNCY Unicycive Therapeutics | Initiates: Buy | $60 | $4.64 | +1,193.10% | 1 | Apr 21, 2025 | |
| MRK Merck & Co. | Reiterates: Buy | $115 | $82.39 | +39.58% | 14 | Apr 17, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Buy | $47 | $14.84 | +216.82% | 8 | Apr 14, 2025 | |
| JNJ Johnson & Johnson | Reiterates: Neutral | n/a | $155.56 | - | 15 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $31 | $18.38 | +68.66% | 1 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.69 | +271.75% | 3 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | n/a | $25.32 | - | 22 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $59 → $61 | $23.65 | +157.93% | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $101 | $98.24 | +2.81% | 6 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $13.44 | - | 5 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.58 | +936.81% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $20 | $9.08 | +120.26% | 9 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $0.60 | +4,225.40% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $9 | $0.72 | +1,144.47% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $1.21 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $21.24 | -10.55% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $129.40 | -24.27% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $29.00 | +17.24% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $1.60 | +525.00% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $103.91 | -52.84% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $779.28 | -54.32% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $4.73 | +26.85% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $14.76 | +943.36% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $9.23 | +62.60% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $28.56 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $17.05 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $3.99 | +276.41% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $47.63 | +28.07% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $1.15 | +8,856.52% | 3 | Jan 17, 2018 |
Jade Biosciences
Jun 16, 2025
Upgrades: Buy
Price Target: $14
Current: $10.84
Upside: +29.15%
Savara
May 28, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.10
Upside: +280.95%
Amgen
May 20, 2025
Assumes: Neutral
Price Target: $288
Current: $296.85
Upside: -2.98%
ANI Pharmaceuticals
May 12, 2025
Reiterates: Buy
Price Target: $86
Current: $65.26
Upside: +31.79%
Valneva SE
May 8, 2025
Maintains: Buy
Price Target: $15 → $14
Current: $5.81
Upside: +140.96%
AbbVie
Apr 29, 2025
Maintains: Buy
Price Target: $214 → $216
Current: $190.75
Upside: +13.24%
Unicycive Therapeutics
Apr 21, 2025
Initiates: Buy
Price Target: $60
Current: $4.64
Upside: +1,193.10%
Merck & Co.
Apr 17, 2025
Reiterates: Buy
Price Target: $115
Current: $82.39
Upside: +39.58%
Travere Therapeutics
Apr 14, 2025
Reiterates: Buy
Price Target: $47
Current: $14.84
Upside: +216.82%
Johnson & Johnson
Apr 2, 2025
Reiterates: Neutral
Price Target: n/a
Current: $155.56
Upside: -
Mar 25, 2025
Initiates: Buy
Price Target: $31
Current: $18.38
Upside: +68.66%
Mar 20, 2025
Reiterates: Buy
Price Target: $10
Current: $2.69
Upside: +271.75%
Mar 18, 2025
Reiterates: Buy
Price Target: n/a
Current: $25.32
Upside: -
Feb 27, 2025
Maintains: Buy
Price Target: $59 → $61
Current: $23.65
Upside: +157.93%
Feb 25, 2025
Reiterates: Buy
Price Target: $101
Current: $98.24
Upside: +2.81%
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $13.44
Upside: -
Sep 10, 2024
Initiates: Buy
Price Target: $6
Current: $0.58
Upside: +936.81%
Sep 7, 2023
Maintains: Neutral
Price Target: $19 → $20
Current: $9.08
Upside: +120.26%
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $0.60
Upside: +4,225.40%
Apr 3, 2023
Maintains: Buy
Price Target: $8 → $9
Current: $0.72
Upside: +1,144.47%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $1.21
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $21.24
Upside: -10.55%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $129.40
Upside: -24.27%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $29.00
Upside: +17.24%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $1.60
Upside: +525.00%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $103.91
Upside: -52.84%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $779.28
Upside: -54.32%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $4.73
Upside: +26.85%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $14.76
Upside: +943.36%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $9.23
Upside: +62.60%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $28.56
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $17.05
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $3.99
Upside: +276.41%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $47.63
Upside: +28.07%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $1.15
Upside: +8,856.52%